Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Devjit Tripathy; Carolina Solis-Herrera; Robert E.J. Ryder

doi:10.2337/ds20-0078

Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Devjit Tripathy, Carolina Solis-Herrera, Robert E.J. Ryder

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.

Original language	English (US)
Pages (from-to)	243-247
Number of pages	5
Journal	Diabetes Spectrum
Volume	34
Issue number	3
DOIs	https://doi.org/10.2337/ds20-0078
State	Published - Aug 2021

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.2337/ds20-0078

Cite this

@article{55ee30d4bb7b4d1b994475de6a10bb7a,

title = "Cardioprotective Effects of Pioglitazone in Type 2 Diabetes",

abstract = "Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.",

author = "Devjit Tripathy and Carolina Solis-Herrera and Ryder, {Robert E.J.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the American Diabetes Association.",

year = "2021",

month = aug,

doi = "10.2337/ds20-0078",

language = "English (US)",

volume = "34",

pages = "243--247",

journal = "Diabetes Spectrum",

issn = "1040-9165",

publisher = "American Diabetes Association Inc.",

number = "3",

}

TY - JOUR

T1 - Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

AU - Tripathy, Devjit

AU - Solis-Herrera, Carolina

AU - Ryder, Robert E.J.

PY - 2021/8

Y1 - 2021/8

N2 - Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.

AB - Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.

UR - http://www.scopus.com/inward/record.url?scp=85122186298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122186298&partnerID=8YFLogxK

U2 - 10.2337/ds20-0078

DO - 10.2337/ds20-0078

M3 - Article

AN - SCOPUS:85122186298

SN - 1040-9165

VL - 34

SP - 243

EP - 247

JO - Diabetes Spectrum

JF - Diabetes Spectrum

IS - 3

ER -

Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this